Observational Recruiting
NCT07117136 on ClinicalTrials.gov
Blinatumomab Consolidation in Real World
Official title: Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
- Sponsor: Medical College of Wisconsin
- Enrollment: 200 (Estimated)
- Study start: 2025-08-28 (Actual)
- Primary completion: 2029-05-14 (Estimated)
- Study completion: 2029-05-14 (Estimated)
- Allocation: N/a
- InterventionModel: N/a
- Masking: None
- PrimaryPurpose: Other
Brief Summary
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Conditions
- B-Cell Acute Lymphoblastic Leukaemia
Primary Outcome Measures
-
Percentage of participants with complete remission
(5 years or e.g., 1 year after closure of study)
Complete remission as defined by patients having no lymphoblasts in the marrow or blood
Countries
United States
Locations and Investigators
-
Mayo Clinic Cancer Center, Jacksonville, United States (Recruiting)
- Talha Badar, MD
- Talha Badar, MD (Principal Investigator)
-
Northwestern University, Chicago, United States (Recruiting)
- Shira Dinner, MD
- Shira Dinner, MD (Principal Investigator)
-
The University of Chicago, Chicago, United States (Recruiting)
- Anand Patel, MD
- Anand Patel, MD (Principal Investigator)
-
University of Pennsylvania, Philadelphia, United States (Recruiting)
- Camila Ludlow, MPH
- Selina Luger, MD (Principal Investigator)
-
Medical College of Wisconsin, Milwaukee, United States (Recruiting)
- Arielle Program Manager
- Ehab Atallah, MD (Principal Investigator)